Ticker Details
Inovio Pharmaceuticals, Inc. Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
IPO Date:	August 23, 1999
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$111.07M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.15 | 3.64%
Avg Daily Range (30 D):	$0.04 | 3.43%
Avg Daily Range (90 D):	$0.05 | 3.09%

Institutional Daily Volume
Avg Daily Volume:	2.16M
Avg Daily Volume (30 D):	3.35M
Avg Daily Volume (90 D):	2.04M

Trade Size
Avg Trade Size (Sh.):	202
Avg Trade Size (Sh.) (30 D):	420
Avg Trade Size (Sh.) (90 D):	356

Institutional Trades
Total Institutional Trades:	3,233
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$1.76M
Avg Institutional Trade (90 D):	$1.76M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.58M
Avg Closing Trade (30 D):	$1.67M
Avg Closing Trade (90 D):	$1.67M
Avg Closing Volume:	49.21K

News

Apr 7, 2026 @ 7:46 PM Pomerantz Law Firm Announces the Filing of a Class... Source: Pomerantz Llp

Apr 7, 2026 @ 4:00 PM DEADLINE ALERT for PSFE, INO, KD: Law Offices of H... Source: Law Offices Of Howard G. Smith

Apr 6, 2026 @ 9:38 PM Bragar Eagel & Squire, P.C. Urgently Reminds Inves... Source: Bragar Eagel & Squire, P.C.

Apr 6, 2026 @ 8:00 PM Shareholders that lost money on Atara Biotherapeut... Source: Levi & Korsinsky, Llp

Apr 6, 2026 @ 1:32 AM UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDIN... Source: Rosen Law Firm

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.45	$-.28	$.31
Diluted EPS	$-1.45	$-.28	$.31
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-84.93M	$-19.68M	$3.76M
Operating Income / Loss	$-83.72M	$-21.95M	$-17.48M
Cost of Revenue
Net Cash Flow	$-13.64M	$-18M	$7.71M
PE Ratio

Splits
Jan 25, 2024	1:12
Jun 09, 2014	1:4
Jun 06, 2014	1:4
Sep 13, 2004	1:4